Unknown

Dataset Information

A phase Ia dose-escalation trial of Ametumumab (a fully human monoclonal antibody against epidermal growth factor receptor) in patients with advanced solid malignancies.


ABSTRACT:

Background

Epidermal growth factor receptor (EGFR) is a well-known target for cancer treatment. However, the authorized anti-EGFR monoclonal antibodies generally cause several toxic effects, especially severe cutaneous toxicities as well as infusion reactions, and the clinical indications are limited. Here we developed Ametumumab, a fully human recombinant anti-EGFR monoclonal antibody.

Objectives

To assess the safety, tolerability, pharmacokinetics (PK), and immunogenicity of Ametumumab.

Design

A first-in-human phase Ia dose escalation study of Ametumumab in patients with advanced solid malignancies.

Methods

An open-label, first-in-human dose escalation study was done in 22 patients with advanced malignancies who received six ascending dosages ranging from 75

SUBMITTER: Li D 

PROVIDER: S-EPMC10071157 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature